Search

Your search keyword '"F Masi"' showing total 4 results
Start Over Author "F Masi" Publisher sage publications
4 results on '"F Masi"'

1. Shelf Life Prediction of Fresh Italian Pork Sausage Modified Atmosphere Packed

Author

Elena Torrieri, R. Di Monaco, F. Masi, Francesco Villani, Silvana Cavella, and Federica Russo

Subjects
Time Factors, Swine, General Chemical Engineering, Shelf life, Industrial and Manufacturing Engineering, chemistry.chemical_compound, Food Preservation, Animals, Humans, Food microbiology, Food science, Pork sausage, Kinetic model, Atmosphere, Food Packaging, Food preservation, Carbon Dioxide, Consumer Behavior, Hydrogen-Ion Concentration, Meat Products, Kinetics, Odor, chemistry, Modified atmosphere, Odorants, Carbon dioxide, Food Microbiology, Environmental science, Food Science
Abstract

The shelf life of fresh Italian pork sausages packed in modified atmosphere was studied. Samples were packed using different levels of oxygen (high and low) with different levels of carbon dioxide (high-low) in the atmospheres headspace and were stored at 4 °C for 9 days. Microbial, physiochemical and sensory parameters were analyzed during storage. A consumer test was performed to determine the critical acceptability levels. Sensory data were mathematically modelled to estimate product shelf life. A first-order kinetic model and a Weibull-type model aptly described, respectively, the changes in fresh pork sausage odor and color over storage time. These models may be used to predict the sensory shelf life of fresh pork sausage. Results showed that 20% O2 and 70% CO2 extend fresh pork sausage shelf life to 9 days at 4 °C. The microbial quality of the samples at the critical sensory level of acceptability was within the range of microbial acceptability.

Published
2011
Full Text
View/download PDF

2. Dislipemia in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Pharmacological Therapy (Simvastatin) versus Hemodialysis

Author

G Romei Longhena, F. Masi, L. Maltagliati, F. Civardi, R. Cimino, and R. Marangoni

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, Continuous ambulatory peritoneal dialysis, Urology, General Medicine, medicine.disease, Extracorporeal, Uremia, Peritoneal dialysis, Surgery, Nephrology, Simvastatin, Ambulatory, medicine, Hemodialysis, Complication, business, medicine.drug
Abstract

Peritoneal dialysis can worsen disllpemia, which is frequent in chronically uremic patients. In order to verify the therapeutic possibilities, we retrospectively studied 20 chronically uremic patients who had been previously treated with continuous ambulatory peritoneal dialysis (CAPO) and who had developed an IV-type dislipemia. Twelve have continued CAPO treatment and have been simultaneously treated with simvastatin; 8 have withdrawn from CAPO and have begun HO, without any antidislipemic pharmacological support. The results, after 3, 6, 12, and 18 months of treatment, showed the following: In patients treated with CAPO and simvastatin, highly significant decreases were noted in total cholesterol (T-cho) and triglycerides (TG) (p

Published
1993
Full Text
View/download PDF

3. Advances in the diagnosis of acute aortic syndromes: Role of imaging techniques.

Author

Ciccone MM, Dentamaro I, Masi F, Carbonara S, and Ricci G

Subjects
Acute Disease, Aortography methods, Computed Tomography Angiography, Echocardiography, Transesophageal, Humans, Magnetic Resonance Angiography, Predictive Value of Tests, Prognosis, Syndrome, Ultrasonography, Doppler, Color, Ultrasonography, Interventional, Aortic Diseases diagnostic imaging, Diagnostic Imaging methods
Abstract

Aortic diseases include a wide range of pathological conditions: aortic aneurysms, pseudoaneurysms, acute aortic syndromes, atherosclerotic and inflammatory conditions, genetic diseases and congenital anomalies. Acute aortic syndromes have acute onset and may be life-threatening. They include aortic dissection, intramural haematoma, penetrating aortic ulcer and traumatic aortic injury. Pain is the common denominator to all acute aortic syndromes. Pain occurs regardless of age, gender and other associated clinical conditions. In this review, we deal with the main findings in the clinical setting and the most recent indications for diagnostic imaging, which are aimed to start an appropriate treatment and improve the short- and long-term prognosis of these patients., (© The Author(s) 2016.)

Published
2016
Full Text
View/download PDF

4. Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis.

Author

Marangoni R, Civardi F, Masi F, Cimino R, Maltagliati L, and Romei Longhena G

Subjects
Female, Humans, Hyperlipidemias blood, Hyperlipidemias etiology, Lipids blood, Lovastatin therapeutic use, Male, Retrospective Studies, Simvastatin, Uremia complications, Uremia therapy, Hyperlipidemias drug therapy, Hypolipidemic Agents therapeutic use, Lovastatin analogs & derivatives, Peritoneal Dialysis, Continuous Ambulatory adverse effects, Renal Dialysis
Abstract

Peritoneal dialysis can worsen dislipemia, which is frequent in chronically uremic patients. In order to verify the therapeutic possibilities, we retrospectively studied 20 chronically uremic patients who had been previously treated with continuous ambulatory peritoneal dialysis (CAPD) and who had developed an IV-type dislipemia. Twelve have continued CAPD treatment and have been simultaneously treated with simvastatin; 8 have withdrawn from CAPD and have begun HD, without any antidislipemic pharmacological support. The results, after 3, 6, 12, and 18 months of treatment, showed the following: in patients treated with CAPD and simvastatin, highly significant decreases were noted in total cholesterol (T-cho) and triglycerides (TG) (p < 0.001), and highly significant increases were noted in HDL-cholesterol (HDL-cho) (p < 0.005) and apolipoprotein-A1 (Apo-A1) (p < 0.01). In patients treated with HD, only slightly significant decreases were noted in T-cho (p < 0.01) and TG (p < 0.02), a slightly significant increase in Apo-A1 (p < 0.05), and no significant change in HDL-cho. Apolipoprotein-B showed no change in the two groups. Therefore, patients undergoing CAPD, with dislipemia only, can continue the treatment, because simvastatin is capable of correcting dislipemia, while those patients who have displemia as well as other complications strictly due to CAPD must abandon treatment and must be transferred to extracorporeal methods.

Published
1993

Catalog

Books, media, physical & digital resources
See catalog results